<DOC>
	<DOCNO>NCT01389687</DOCNO>
	<brief_summary>The aim study assess immunogenicity safety SP059 three-dose primary booster vaccination Japanese infant age 3 68 month . Primary objective : - To assess seroprotection rate polio type 1 , 2 3 90 % approximately one month follow three dose primary vaccination series inactivate polio vaccine ( IPV ) . Secondary objective : - To describe immunogenicity ( term seroprotection / seroconversion vaccine response rate Geometric Mean Titers ) IPV primary vaccination booster vaccination . - To describe safety dose IPV .</brief_summary>
	<brief_title>Study SP059 Given Subcutaneously Three-dose Primary Booster Vaccination Infants Japan</brief_title>
	<detailed_description>Study participant receive three dos inactivate polio vaccine ( IPV ) ( visit give 3-8 week apart ) three-dose primary vaccination start 3-68 month age follow single dose IPV booster vaccination 6-18 month completion three-dose primary vaccination . Subjects observed Investigator sub-Investigator 30 minute follow vaccine injection . The duration participant 's participation trial approximately 1 year .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 3 68 month inclusive ( recommend 3 8 month ) day inclusion Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure Exclusion Criteria : Fever ≥ 37.5°C ( axillary temperature ) day inclusion Any serious disease whether acute chronic History poliomyelitis infection History life threaten reaction vaccine contain substance study vaccine History anaphylaxis allergy study vaccine component Previous vaccination poliomyelitis diseases infection trial vaccine another vaccine Congenital current/ previous acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Participation another clinical trial precede trial inclusion Planned participation another clinical trial present trial period Blood bloodderived product receive past current plan administration trial ( include immunoglobulin ) . Any vaccination live vaccine within past 27 day precede first trial vaccination . Any vaccination inactivate vaccine within past 6 day precede first trial vaccination . Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or human immunodeficiency virus infection Subject ineligible accord investigator 's clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>68 Months</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>Inactivated polio vaccine</keyword>
	<keyword>Polio</keyword>
	<keyword>Poliovirus</keyword>
</DOC>